Calcium Silicate Nanopowder

Calcium Silicate Nanopowder

Calcium silicates Nanopowder are a class of inorganic compounds composed of elements Ca, Si and O and sometimes additional H elements. Calcium silicates Nanopowder have a variety of forms with various chemical compositions; among these many common ones include CaSiO3, Ca2SiO4, Ca3SiO5 and Ca3Si2O7. Calcium silicates Nanopowder usually occur in the hydrated form containing various percentages of water of crystallization. Calcium silicates Nanopowder materials have advantages such as high biocompatibility, bioactivity and biodegradability, high drug carrying capacity and pH sensitive drug release behavior. Silica-based mesoporous materials have been studied as drug carriers due to their high specific surface area, large pore volume and good biocompatibility. However, surfactants are used as templates to prepare mesoporous structures and the surfaces of the pore walls are generally modified or functionalized with organic groups to facilitate drug absorption and drug release control. However, residual surfactants and introduced organic groups can cause cytotoxicity for clinical applications. For bone-implantable drug delivery systems, silica bioactivity is unsatisfactory and clinically applicable poly (methyl methacrylate) systems have disadvantages such as poor bioactivity and low biodegradability that must be removed by a second surgery to avoid infections. Furthermore, the incorporation of CaO into SiO2 structures can improve bioactivity. Ca2 + cations on the surface of calcium silicate materials can act as intrinsic active sites to effectively adsorb drug molecules with -COOH or -OH groups, such as ibuprofen, aspirin and amoxicillin. Calcium silicate materials have many applications, for example they are commonly used as a safe alternative to asbestos for high temperature insulation and fireproofing. In addition, calcium silicate materials act as absorbents, bulking agents and opacifiers in cosmetic formulations. The United States. The Food and Drug Administration (FDA) reported 132 formulations containing calcium silicate in 1998, of which 30% were face powders, and calcium silicate is listed in the OTC Active Ingredient Status Report as an external analgesic and skin protective.